HC Wainwright Reaffirms “Buy” Rating for PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $21.00 price target on the stock.

Other equities analysts also recently issued reports about the company. StockNews.com downgraded PDS Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, November 9th. B. Riley reduced their price objective on PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, November 25th. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, PDS Biotechnology currently has a consensus rating of “Moderate Buy” and an average target price of $11.67.

PDS Biotechnology Stock Performance

Shares of PDS Biotechnology stock traded down $0.11 during trading hours on Monday, reaching $1.24. The company’s stock had a trading volume of 830,324 shares, compared to its average volume of 260,137. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.84 and a current ratio of 2.84. PDS Biotechnology has a one year low of $1.20 and a one year high of $6.68. The company’s 50 day simple moving average is $1.57 and its 200 day simple moving average is $2.47. The stock has a market cap of $46.20 million, a P/E ratio of -1.06 and a beta of 1.88.

Institutional Trading of PDS Biotechnology

A number of hedge funds and other institutional investors have recently made changes to their positions in PDSB. Geode Capital Management LLC raised its stake in shares of PDS Biotechnology by 9.8% in the 3rd quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock worth $1,586,000 after buying an additional 37,142 shares in the last quarter. XTX Topco Ltd grew its holdings in PDS Biotechnology by 241.8% during the third quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock worth $257,000 after acquiring an additional 47,528 shares during the period. Two Sigma Investments LP raised its position in PDS Biotechnology by 273.5% in the fourth quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock worth $107,000 after acquiring an additional 48,132 shares in the last quarter. Jane Street Group LLC acquired a new stake in PDS Biotechnology in the 4th quarter valued at about $58,000. Finally, Raymond James Financial Inc. bought a new position in shares of PDS Biotechnology during the 4th quarter valued at about $26,000. 26.84% of the stock is currently owned by institutional investors.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.